



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## N-Boc-PEG5-alcohol

|                    |   |       |          |
|--------------------|---|-------|----------|
| Cat. No.:          | HY-141191                                       |       |          |
| CAS No.:           | 1404111-67-6                                    |       |          |
| Molecular Formula: | C <sub>15</sub> H <sub>31</sub> NO <sub>7</sub> |       |          |
| Molecular Weight:  | 337.41  |       |          |
| Target:            | PROTAC Linkers                                  |       |          |
| Pathway:           | PROTAC  |       |          |
| Storage:           | Pure form                                       | -20°C | 3 years  |
|                    |   | 4°C   | 2 years  |
|                    | In solvent                                      | -80°C | 6 months |
|                    |   | -20°C | 1 month  |



### BIOLOGICAL ACTIVITY

|                           |  |             |  |
|---------------------------|--|-------------|--|
| Description               | N-Boc-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> .  |             |  |
| IC <sub>50</sub> & Target | PEGs   | Alkyl/ether |  |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |             |  |

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA